Emibetuzumab (LY2875358) is a humanized bivalent MET antibody of the IgG4 subtype, designed to exhibit potent neutralizing and internalizing capabilities. This antibody effectively inhibits both hepatocyte growth factor (HGF)-dependent and HGF-independent MET pathway activations, thereby impeding tumor growth. Emibetuzumab is primarily utilized in cancer research studies, focusing on its therapeutic potential and mechanism of action in oncogenic signaling and tumor progression.
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody of the IgG4 subtype, designed to exhibit potent neutralizing and internalizing capabilities. This antibody effectively inhibits both hepatocyte growth factor (HGF)-dependent and HGF-independent MET pathway activations, thereby impeding tumor growth. Emibetuzumab is primarily utilized in cancer research studies, focusing on its therapeutic potential and mechanism of action in oncogenic signaling and tumor progression.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
